Targeted sequencing of histologically defined serous endometrial cancer reflects prognosis and correlates with preoperative biopsy

• Published in: Gynecologic oncology reports Vol. 30; p. 100521
• Main Authors: Octeau, David, Abitbol, Jeremie, Amajoud, Zainab, Laskov, Ido, Ferenczy, Alex, Pelmus, Manuela, Eisenberg, Neta, Kessous, Roy, Matanes, Emad, Lau, Susie, Yasmeen, Amber, Lopez-Ozuna, Vanessa, Salvador, Shannon, Gotlieb, Walter H., Kogan, Liron
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 01-11-2019; Elsevier
• Subjects: Case Series; Endometrial cancer; Endometrial sample; Mixed tumor; Molecular profile; Serous; Molecular profile; Serous; Endometrial cancer; Mixed tumor; Endometrial sample
• ISSN: 2352-5789; 2352-5789
• DOI: 10.1016/j.gore.2019.100521

•Preoperative diagnosis of endometrioid carcinoma is common in finally diagnosed serous endometrial cancer.•Endometrioid preoperative sample is associated with better outcome in women finally diagnosed with serous uterine cancer.•Endometrioid preoperative sample is reflected in the mutational profile of final pathology.
The aim of this study was to evaluate the impact of discordant endometrial sampling on the prognosis of patients finally diagnosed with uterine papillary serous carcinoma (UPSC) and to analyze UPSC mutational profile. Retrospective cohort study comparing outcomes of patients post-operatively diagnosed with UPSC and preoperatively diagnosed with endometrioid endometrial cancer (EEC) or UPSC. Genes commonly implicated in carcinogenesis were analyzed in a subgroup of 40 patients post-operatively diagnosed with UPSC, using next generation sequencing. 61 patients with UPSC on post-surgical, final pathology were included in the study. Prior to surgery, 15 were diagnosed with EEC (discordant) and 46 were correctly diagnosed with UPSC (concordant). After a median follow-up of 41.6 months [5.4–106.7], a preoperative diagnosis of EEC was associated with better 3-year progression-free survival (100% vs. 60.9%, P = 0.003) and longer disease free interval (63.5 versus 15 months, P = 0.026) compared to patients with an initial diagnosis of UPSC. Patients with a concordant diagnosis of UPSC were 5 times more likely to progress or die compared to those with a discordant EEC diagnosis (P = 0.02, P = 0.03, respectively), and their tumors were associated with higher rates of TP53 (88.9% vs. 61.5%, P = 0.04), and a lower rate of PTEN (14.8% vs. 38.5%, P = 0.09) and ARID1A (3.7% vs. 23.1%, P = 0.05) mutations. A pre-surgical diagnosis of EEC is associated with improved prognosis in patients with UPSC. Some histologically defined UPSC tumors contain endometrioid-like molecular characteristics that may confer a survival advantage, suggesting a possible need for molecular approaches to better stratify patients into risk groups.